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a b s t r a c t
Objective. This study assessed the efﬁcacy of lenvatinib, a multitargeted tyrosine kinase inhibitor, as secondline therapy in patients with unresectable endometrial cancer. The primary end point was the objective response
rate (ORR) as assessed by independent radiologic review (IRR). Secondary end points included median
progression-free survival (PFS), overall survival (OS), and clinical beneﬁt rate. Exploratory end points examined
the association of baseline levels of plasma biomarkers (50 circulating cytokine and/or angiogenic factors measured by immunoassays) with efﬁcacy outcomes.
Methods. An international, open-label, single-arm, multicenter, phase 2 trial was conducted. Eligible patients
had histologically conﬁrmed unresectable endometrial cancer that relapsed after 1 prior systemic platinumbased chemotherapy. Patients received once-daily oral lenvatinib 24 mg in a 28-day dosing cycle.
Results. There were 133 patients in the study. By IRR, 19 patients had a conﬁrmed objective response for an
ORR of 14.3% (95% CI: 8.8–21.4). Durable stable disease (≥23 weeks) was observed in 31 patients (23.3%) and
the clinical beneﬁt rate was 37.6% (95% CI: 29.3–46.4). Median PFS was 5.6 months (95% CI: 3.7–6.3), and median
OS was 10.6 months (95% CI: 8.9–14.9). The most common (any grade) treatment-related adverse events were
fatigue/asthenia (48%), hypertension (49%), nausea/vomiting (32%), decreased appetite (32%), and diarrhea
(31%). Lower baseline levels of angiopoietin-2 were associated with longer PFS, OS, and a higher ORR.
Conclusions. Patients with recurrent endometrial cancer treated with second-line lenvatinib experienced
modest antitumor activity and treatment was generally well tolerated, with a safety proﬁle consistent with previous studies.
© 2020 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Endometrial cancer primarily afﬂicts older women. The highest incidence is in women aged 45 to 74 years, with a median age at diagnosis
of 62 years [1–3]. If diagnosed early, patients have a 5-year relative survival rate of 95% [1,4].
Endometrial cancer is difﬁcult to treat in the second-line setting. A
phase 3 study of ixabepilone versus paclitaxel or doxorubicin for
second-line treatment of patients with advanced endometrial cancer
was discontinued for futility [5]. Moreover, a phase 3 trial comparing

https://doi.org/10.1016/j.ygyno.2019.12.039
0090-8258/© 2020 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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zoptarelin to doxorubicin also failed to improve the overall survival
(OS) of patients with advanced endometrial cancer [6]. Several other
clinical trials of both targeted therapies and chemotherapeutic regimens
have also demonstrated disappointing outcomes in advanced and recurrent endometrial carcinoma, underscoring the challenging nature
of this disease [7–11].
Though some combination chemotherapies can be associated with
improved objective response rates (ORR), progression-free survival
(PFS), and OS [12,13], their use may result in an increased risk for serious adverse events [12,13]. Regardless of the treatment received, the
clinical prognosis of patients with recurrent or advanced endometrial
cancer remains poor, with a 5-year survival rate of approximately 17%,
a median OS of b12 months [13], and a median PFS of about 4 months
after second-line treatment [5,6]. There is a substantial unmet need
for second-line therapies, including molecularly targeted agents, to
treat and improve the prognosis of patients with recurrent or advanced
endometrial cancer. Some recent trials of immuno-oncology therapies
are promising. The addition of bevacizumab to carboplatin and paclitaxel improved PFS in a phase 2 trial for patients with advanced or recurrent endometrial cancer [14], and a phase 2 trial using selinexor to
treat patients with gynecological cancers showed promising disease
control [15]. Additional trials combining atezolizumab (NCT03603184)
or dostarlimab (NCT03981796) with carboplatin and paclitaxel are
underway.
Vascular endothelial growth factor (VEGF) stimulates angiogenesis, promotes tumor growth, and facilitates metastasis in various
solid cell tumors, including endometrial cancer [16]. Moreover,
VEGF expression is associated with unfavorable histopathological
features and poor prognosis in endometrial cancer [16]. Several
VEGF-targeted therapies exist; however, patients treated with therapies that only target the VEGF-signaling pathway may eventually
develop resistance due to alternate proangiogenic mechanisms, including activation of the ﬁbroblast growth factor (FGF)-signaling
pathway [17], which is known to facilitate angiogenesis. Approximately 12% of patients with endometrial cancer have somatic mutations in FGF receptor-2 [18], further supporting a role for FGF as a
mediator of cancer progression in these patients.
Lenvatinib is an oral multityrosine kinase inhibitor that targets VEGF
receptors 1–3, FGF receptors 1–4, platelet-derived growth factor receptor alpha, RET, and KIT [19–21]. Lenvatinib monotherapy is approved for
the treatment of radioactive iodine-refractory differentiated thyroid
cancer and unresectable hepatocellular carcinoma [22]. Lenvatinib
showed promising antitumor activity in a phase 1 dose-escalation
study in 77 patients with advanced solid tumors, which included 4 patients with endometrial cancer [23]. Currently, 2 ongoing phase 3 trials
of lenvatinib plus pembrolizumab in patients with advanced endometrial cancer are underway (ClinicalTrials.gov: NCT03517449 and
NCT03884101). Our phase 2 study evaluated the efﬁcacy and safety of
single-agent lenvatinib in patients with recurrent or advanced endometrial cancer after failure of 1 prior platinum-based therapy.

2.2. Patients
Eligible patients (aged ≥18 years) had histologically conﬁrmed diagnosis of endometrial cancer and had disease progression after 1 prior,
platinum-based, systemic chemotherapy for metastatic or primary
unresectable endometrial cancer. Patients who received platinumbased chemotherapy in the (neo)adjuvant setting and had disease progression within 1 year were eligible; those who progressed after 1 year
must have received 1 additional chemotherapy to be eligible. Other key
inclusion criteria included the presence of measurable disease per Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST v1.1)
and an Eastern Cooperative Oncology Group performance status ≤2. Patients were excluded if they had received prior VEGF-inhibitors or N1
prior systemic chemotherapy for metastatic or primary unresectable
endometrial carcinoma. Patients were excluded if they were not fully
recovered from prior radiotherapy; had an antitumor therapy or
major surgery within 3 weeks of enrollment; received any investigational drug b30 days prior to treatment initiation; had a malignancy
within the past 2 years; or had a condition that could interfere with
the study.
2.3. Study end points and assessments
The primary end point was the ORR deﬁned as the percentage of patients with a best overall response (BOR) of complete response (CR) or
partial response (PR) based on RECIST v1.1, as determined by independent radiologic review (IRR). A BOR of CR was conﬁrmed by a subsequent CR assessment at least 4 weeks later. A BOR of PR was
conﬁrmed by a subsequent CR or PR assessment at least 4 weeks later.
Secondary efﬁcacy end points were PFS, OS, stable disease (SD; lasting ≥7 weeks), clinical beneﬁt rate, and disease control rate (as assessed
by IRR and RECIST v1.1). The clinical beneﬁt rate was deﬁned as the percentage of patients with a CR or PR, or durable SD (≥23 weeks). The disease control rate was deﬁned as the percentage of patients with a CR, PR,
or SD. Efﬁcacy was also assessed by the investigator (secondary
method) using RECIST v1.1. Tumors were evaluated using computed tomography or magnetic resonance imaging every 8 weeks.
The safety end point consisted of monitoring and recording all adverse events. Treatment-emergent adverse events (TEAEs) were
coded using the Medical Dictionary for Regulatory Affairs (version
15.0) and graded for severity using the National Cancer Institute Common Terminology Criteria for Adverse Event (version 4.0). The relationship of a TEAE to the study drug was determined by the investigator.
Exploratory analyses to identify biomarkers potentially predictive of
PFS, OS, BOR, or maximum tumor shrinkage were conducted. Plasma
samples were collected at baseline, day 1 of dosing cycle 2, and posttreatment. Plasma samples were evaluated using an enzyme-linked immunosorbent assay or multiplex bead-based immunoassay that was
comprised of a panel of 50 circulating cytokines and/or angiogenic factors. These circulating factors were selected based on known lenvatinib
targets, key factors involved in angiogenesis and endothelial cell function, and previous studies [24,25].

2. Methods
2.4. Statistical analyses
2.1. Study design
In this open-label, single-arm, phase 2 study, patients with advanced
or recurrent endometrial cancer received 24 mg oral lenvatinib oncedaily in a 28-day dosing cycle (ClinicalTrials.gov identiﬁer:
NCT01111461). Patients were enrolled across 69 sites in Belgium,
Bulgaria, Hungary, Poland, Romania, Russia, Ukraine, and the United
States. The study was conducted in accordance with the International
Conference on Harmonisation Good Clinical Practice guidelines, and
local institutional review board or independent ethics committee standards of practice. All patients provided written informed consent prior
to study enrollment.

A sample size of 130 patients was planned, based on Simon's optimal
2-stage design [26], and a null hypothesis rate of ≤10% against an alternative response rate of ≥20%. According to this design, if b6 responses
were observed based on investigator assessment among the ﬁrst 47 patients, then the treatment would be rejected, and the study
discontinued. At the end of the study, if ≥19 responses were observed
among 130 patients who met the intent-to-treat (ITT) criteria (as patients who received ≥1 dose of lenvatinib), the treatment would be considered active in this population.
Efﬁcacy analyses were performed in the ITT population. Safety analyses were performed on the safety populations, deﬁned as patients who
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received any dose of lenvatinib and had ≥1 postbaseline safety evaluation. PFS and OS were estimated using Kaplan–Meier statistics. Safety
results and biomarker analyses were summarized using descriptive statistics. P-values for correlations between cytokines and/or angiogenic
factors and OS or PFS were calculated using a univariate Cox proportional hazard model. The exact Wilcoxon test was used for BORs and
Spearman's rank correlation test was used for maximum tumor
shrinkage.
3. Results
3.1. Patients
Between March 3, 2010 and May 21, 2012 (data cutoff date), 133 patients received lenvatinib, 82 (62%) of whom completed the treatment
phase (Fig. S1). Patient demographics and baseline characteristics are
listed in Table 1.
3.2. Efﬁcacy
The primary end point of ORR was 14.3% (n = 19/133; 95% CI:
8.8–21.4) as assessed by IRR, and 21.1% (n = 28/133; 95% CI:
14.5–29.0) as assessed by the clinical trial investigators (Table 2).
There appeared to be a greater ORR in patients without baseline liver lesions (26% [n = 23/90]; 95% CI: 16.9–35.8) versus those with liver metastases (12% [n = 5/43]; 95% CI: 3.9–25.1) as assessed by investigator.
The ORR did not vary greatly across histologic subtype (15% vs 14% for
endometrioid and non-endometrioid cancers, respectively). The median duration of response was 7.2 months (95% CI: 4.5–not estimable)
and 8.0 months (95% CI: 3.8–11.3) by IRR and investigator assessment,
respectively (Table 2). Most patients showed a decrease in tumor size
based on both IRR and investigator assessment (Fig. 1A and B) with a
median maximum tumor shrinkage of −20.3% by IRR and −21.0% by investigator assessment (range: −100 to 25.8% and −100 to 57.0%, respectively; Table 2). Median PFS was 5.6 months (95% CI: 3.7–6.3) and
5.4 months (95% CI: 3.7–6.7), as assessed by IRR and investigator, respectively (Fig. 2A). The 6-month PFS rate was 41% (95% CI: 32% to
51%), by both investigator and independent assessment. In an updated
analysis (November 2012), 79 deaths had occurred. The median OS
was 10.6 months (95% CI: 8.9–14.9; Fig. 2B), with a survival rate of
74% (95% CI: 66.0–81.2) at 6 months and 45% (95% CI: 36.5–54.0) at
1 year (Fig. 2B).
3.3. Safety
Patients were exposed to lenvatinib for a median duration of
3.7 months (range: 0.2 to 15.5 months; Table S1). TEAEs occurred in
95% of patients; the most frequently occurring (N5% of patients) ≥ grade
3 TEAEs were hypertension (33%), fatigue (12%), asthenia (10%), abdominal pain (6%), proteinuria (8%), and dehydration (6%). Of these, hypertension, proteinuria, fatigue, and diarrhea were predeﬁned TEAEs of
special interest. TEAEs led to study-drug interruptions in 59% (n = 78/
133) of patients and 30% (n = 40/133) required a dose reduction. Treatment discontinuation due to a TEAE was reported for 31% (n = 41/133)
of patients.
Treatment-related TEAEs were reported in 87% (n = 116/133) of patients (Table 3). The 5 most frequently reported treatment-related
TEAEs were fatigue/asthenia (48%; n = 64/133), hypertension (49%;
n = 65/133), nausea/vomiting (32%; n = 42/133), decreased appetite
(32%; n = 43/133), and diarrhea (31%; n = 41/133; Table 3).
Treatment-related TEAEs with grade ≥ 3 were reported in 59% (n =
78/133) of patients, of which hypertension occurred most frequently
(31%; n = 41/133; Table 3). Treatment-related ﬁstulas occurred in 2 patients: gastrointestinal ﬁstula (n = 1) and genital tract ﬁstula (n = 1).
Treatment-related TEAEs leading to discontinuation were reported for
18% (n = 24/133) of patients. Treatment-related TEAEs leading to
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Table 1
Patient demographic and baseline characteristics (ITT population).
Parameter

Lenvatinib 24 mg/day
(N = 133)

Median age (range), years
Race, n (%)
White
Black
Other
ECOG performance status score, n (%)
0
1
2
Histology, n (%)
Endometrioid
Papillary Serous
Clear cell
Other
Adenocarcinoma
Adenocarcinoma, poorly differentiated
Endometrial adenocarcinoma
Papillary adenocarcinoma
Polypoid adenocarcinoma
Poorly differentiated adenocarcinoma
Locally advanced lesions, n (%)a
Metastatic lesions, n (%)
Liver
Bone
Pelvis
Other
Lung
Lymph node
Spleen
Number of prior chemotherapy regimens, n (%)b
1
2
Type of prior therapyc, n (%)
Adjuvant
Therapeutic
Neoadjuvant
Maintenance
Unknown
Median time (range)
Since ﬁrst diagnosis, years
Duration of prior therapy, months
Median time from end of last therapy to ﬁrst dose
(range)
Anticancer treatment
Radiotherapy treatment

62.0 (38–80)

Prior chemotherapies, n (%)
Carboplatin
Paclitaxel
Cisplatin
Doxorubicin
Carboplatin + paclitaxel
Epirubicin
Cisplatin + doxorubicin
Docetaxel
Best response with prior therapy, n (%)
Complete response
Partial response
Stable disease
Progressive disease
Unknown/not evaluable/not applicable

112 (84)
10 (8)
11 (8)
50 (38)
71 (53)
12 (9)
89 (67)
24 (18)
10 (8)
10 (8)
5 (4)
1 (1)
1 (1)
1 (1)
1 (1)
1 (1)
13 (10)
119 (89)
43 (32)
8 (6)
1 (1)
106 (80)
63 (47)
66 (50)
9 (7)
132 (99)
1 (1)
26 (20)
118 (89)
8 (6)
2 (2)
3 (2)
1.7 (0−12)
3.7 (0.1–16.1)

23.6 (2.7–444.6) weeks
15.7 (1.2–138.7)
months
80 (60)
64 (48)
47 (35)
43 (32)
10 (8)
6 (5)
4 (3)
3 (2)
18 (14)
21 (16)
36 (27)
37 (28)
21 (16)

ECOG, Eastern Cooperative Oncology Group; ITT, intent-to-treat.
a
Patients who had locally advanced regions exclusively at baseline.
b
Patient received 2 prior systemic chemotherapy regimens: a platinum-based regimen
in the adjuvant setting for unresectable disease and systemic topotecan therapy before
enrollment.
c
Numbers are not additive; some patients may have had N1 type of prior therapy
(e.g., adjuvant/neoadjuvant only, therapeutic only, adjuvant/neoadjuvant + therapeutic
only, therapeutic + maintenance only, or unknown).

discontinuation are summarized in Table S2. Three deaths were considered
probably related to the study drug (Table 3): one due to asthenia, one due
to deterioration of general physical health, and one due to renal failure.
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Table 2
Summary of tumor responses as assessed by IRR or investigator using RECIST v1.1 (ITT
population).
Response category

Objective response rate, n (%)
95% CI
Best overall response, n (%)
Complete response
95% CI
Partial response
95% CI
Progressive disease
95% CI
Stable disease (≥7 weeks)
95% CI
Durable stable disease (≥23 weeks)
95% CI
Clinical beneﬁt ratea, n (%)
95% CI
Disease control rateb, n (%)
95% CI
Median duration of response, monthsc
95% CI
Median time to response, monthsd
95% CI
Median maximum tumor shrinkage
(range), %

Lenvatinib 24 mg/day (N = 133)
IRR

Investigator

19 (14.3)
8.8–21.4

28 (21.1)
14.5–29.0

1 (0.8)
0–4.1
18 (13.5)
8.2–20.5
24.0 (18.0)
11.9–25.6
62 (46.6)
37.9–55.5
31 (23.3)
16.4–31.4
50 (37.6)
29.3–46.4
81 (60.9)
52.1–69.2
7.2
4.5–NE
1.8
1.7–3.2
−20.3 (−100,
25.8)

2 (1.5)
0.2–5.3
26 (19.5)
13.2–27.3
16 (12.0)
7.0–18.8
60 (45.1)
36.5–54.0
31 (23.3)
16.4–31.4
59 (44.4)
35.8–53.2
88 (66.2)
57.5–74.1
8.0
3.8–11.3
1.9
1.7–2.3
−21.0 (−100,
57.0)

CI, conﬁdence interval; IRR, independent radiologic review; ITT, intent-to-treat; NE, not
estimable; RECIST v1.1, Response Evaluation Criteria In Solid Tumors version 1.1.
a
Clinical beneﬁt rate is deﬁned as the proportion of patients who achieved complete
response, partial response, or durable stable disease lasting ≥23 weeks.
b
Disease control rate is deﬁned at the proportion of patients who achieved complete
response, partial response, or stable disease lasting at least 7 weeks.
c
Among responders.
d
Best overall response, by Investigator assessment, N = 28; by IRR, N = 19.

3.4. Biomarkers
After 1 cycle of lenvatinib treatment, a change from baseline levels
was observed in 18 of the 50 circulating cytokine and/or angiogenic factors (CAFs) tested (Fig. S2). Among the 18 CAFs that changed from baseline to cycle 2, day 1, angiopoietin-2 (Ang-2 and ANG2[90] are the same
analyte measured using different assay platforms) was the only serum
biomarker where baseline plasma levels correlated with 4 clinical outcome measurements of PFS, OS, BOR, and maximum tumor shrinkage
(Table S3). Quartile analysis demonstrated an improvement in median
PFS (Fig. 3A) and OS (Fig. 3B) in patients with lower baseline
angiopoietin-2 levels Fig. 3. Notably, the ORR for patients with lower
baseline angiopoietin-2 levels was 26.9% (95% CI: 15.6–41.0). In contrast, ORR was 5.7% (95% CI: 1.6–14.0) for patients with higher
angiopoietin-2 levels (using a simulated cutoff value of 2082.5 pg/mL
based on receiver operating characteristics analysis) (Table S4).

4. Discussion
This phase 2 study conﬁrmed that lenvatinib has demonstrated antitumor activity as a second-line treatment for patients with recurrent or
advanced endometrial cancer. Lenvatinib was generally well tolerated
in this patient population and had a safety proﬁle consistent with previous trials using lenvatinib monotherapy for various solid tumor types
[27,28]. As expected with VEGF-inhibitor therapies, hypertension was
the most frequently reported treatment-related TEAE with grade ≥ 3 severity [29]. Treatment-related TEAEs led to study discontinuation in 24
patients (18%), with hypertension being the most common reason for
discontinuation (n = 5; Table S2), followed by grade 4 pulmonary embolism (n = 3; Table S2). Most toxicities were manageable with studydrug dose adjustments.

Treatment with lenvatinib was associated with a 21% (n = 28/133)
ORR by investigator assessment and an ORR of 14% (n = 19/133) by IRR;
these responses were durable, lasting a median of 7.2–8 months. In addition, the median PFS was 5.6 months and the median OS was
10.6 months. Among the 19 patients who were classiﬁed by IRR as having an objective response of either PR or CR in this study, 3 had a previous PR to ﬁrst-line therapy. In response to lenvatinib treatment in this
study, 62 patients (46.6%) achieved stable disease (≥7 weeks); 12 of
these patients had a prior CR and 9 had a prior PR to ﬁrst-line therapy.
Acknowledging the limitations of cross-study comparisons, our ﬁndings
are similar to those observed with other VEGF-targeted therapies in
clinical trials for endometrial cancer conducted at the time of this
study [30]. For example, in patients with recurrent or persistent endometrial cancer, bevacizumab treatment resulted in an ORR of 14%, a median PFS of 4.2 months, and a median OS of 10.5 months [30]. A phase 2
trial of bevacizumab in combination with carboplatin and paclitaxel for
patients with advanced or recurrent endometrial cancer found that the
addition of bevacizumab led to a PFS of 13.0 months and an ORR of
72.7% [14]. Thus, there remained an unmet need for effective therapies
for patients with advanced or recurrent endometrial cancer.
Although single-agent therapy trials, including this one, have shown
only modest anticancer beneﬁts, recent trials using a combination regimen of lenvatinib and pembrolizumab are more promising [31]. An ongoing phase 1b/2 study (NCT02501096) of lenvatinib plus
pembrolizumab, an anti-PD-1 antibody, has demonstrated promising
antitumor activity in patients with previously treated advanced endometrial cancer. The study reported that among patients who were not
microsatellite instability-high (MSI-H) or mismatch repair deﬁcient
(dMMR), there was an ORR of 37.2% (95% CI: 27.5–47.8) [31]. In addition, a phase 1 study evaluating the safety and efﬁcacy of lenvatinib
plus paclitaxel in patients with recurrent gynecological cancers, including endometrial cancer, is currently underway (NCT02788708). There is
evidence that lenvatinib may have some immunological activity, which
may be contributing to its activity in this combination therapy. Treatment with lenvatinib signiﬁcantly increased the percentage of IFN-γsecreting CD8+ T cells and decreased the percentage of tumorassociated macrophages in the CT26 model [32]. In the Hepa1-6
model, treatment with lenvatinib decreased the population of monocytes and macrophages and increased the population of CD8+ T cells
[32,33].
In conclusion, in patients with recurrent or advanced endometrial
cancer, lenvatinib treatment following platinum-based therapy demonstrated antitumor activity comparable with other agents in its class and
had a manageable safety proﬁle. Our results suggest that future efforts
should focus on combination therapies, including use of lenvatinib, in
patients with recurrent or advanced endometrial cancer. This recommendation is supported further by the recent accelerated approval of
the combination of lenvatinib plus pembrolizumab by the United
States Food and Drug Administration for the treatment of patients
with advanced endometrial cancer that is not MSI-H or dMMR who
have progressed following 1 prior systemic therapy and are not eligible
for curative surgery or radiation [22]. Additionally, 2 randomized phase
3 trials of lenvatinib combined with pembrolizumab are currently ongoing in patients with advanced endometrial carcinoma (NCT03517449
and NCT03884101).
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ygyno.2019.12.039.
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Fig. 2. Kaplan–Meier estimate of progression-free survival (A), and overall survival (B) in the ITT population. IRR, independent radiologic review; ITT, intent-to-treat.
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Fig. 3. Kaplan–Meier estimates of PFS (A) or OS (B) by angiopoietin-2 levels (Ang-2)a at baseline, as assessed by the investigator (ITT population). Ang-2, angiopoietin-2; CI, conﬁdence
interval; ITT, intent-to-treat; NE, not estimable; OS, overall survival; PFS, progression-free survival. a As assessed by enzyme-linked immunosorbent assay.
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Table 3
Summary of treatment-related adverse events (by preferred term for any grade occurring
in ≥5% of the population; safety analysis set).
Parameter, n (%)

Lenvatinib (N = 133)

Treatment-related TEAEs
Grade ≥ 3
Serious adverse events
Deathsa
Treatment-related TEAEs leading to:
Dose interruption
Dose reduction
Treatment discontinuation

116 (87)
78 (59)
36 (27)
3 (2)
71 (53)
38 (29)
24 (18)

Treatment-related TEAEs by preferred term

Any grade

Grade ≥ 3

Fatigue/astheniab
Hypertension
Nausea/vomiting
Decreased appetite
Diarrhea
Abdominal/upper abdominal painc
Headache
Proteinuria
Stomatitis
Dysphonia
Decreased weight
Hypothyroidism
Dry mouth
Dizziness
Dysgeusia
Constipation
Palmar-plantar erythrodysesthesia syndrome
Thrombocytopenia
Epistaxis
Peripheral edema
Dehydration
Increased blood thyroid-stimulating hormone

64 (48)
65 (49)
42 (32)
43 (32)
41 (31)
33 (25)
29 (22)
28 (21)
27 (20)
22 (17)
21 (16)
21 (16)
15 (11)
15 (11)
15 (11)
13 (10)
10 (8)
10 (8)
9 (7)
8 (6)
8 (6)
8 (6)

21 (16)
41 (31)
5 (4)
2 (2)
5 (4)
4 (3)
2 (2)
9 (7)
4 (3)
0
3 (2)
1 (1)
0
0
0
0
3 (2)
2 (2)
0
0
5 (4)
1 (1)

TEAE, treatment-emergent adverse event.
a
Deaths were considered related to adverse events of asthenia, deterioration in general
physical health, and renal failure, respectively. Upon review of the available information
for these patients, it was determined that advanced disease and disease progression
may also have contributed to the events.
b
Pooled asthenia/fatigue includes the following preferred terms: asthenia, fatigue, and
lethargy.
c
Pooled abdominal/upper abdominal pain includes the following preferred terms: abdominal pain, upper abdominal pain, and gastrointestinal pain.
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